INOVIO Reports Inducement Grant Under Inducement Plan

Rhea-AI Summary

INOVIO (NASDAQ:INO) announced an inducement equity award under its 2022 Inducement Plan with a grant date of October 31, 2025.

The Compensation Committee approved an option to purchase 3,000 shares of common stock at an exercise price of $2.35 (the closing price on October 31, 2025). The option vests in thirds over three years (one-third on each of the first, second and third anniversaries) and is subject to continued employment and the Inducement Plan option agreement terms. The award was made to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

PLYMOUTH MEETING, Pa., Oct. 31, 2025 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan (the "Inducement Plan").

The Compensation Committee of INOVIO's Board of Directors has approved the award of an option to purchase 3,000 shares of common stock with a grant date of October 31, 2025 (the "Grant Date"), to a newly hired employee in accordance with Nasdaq Listing Rule 5635(c)(4).

The stock option has an exercise price of $2.35, the closing price of INOVIO's common stock on October 31, 2025. The stock option will vest over a three-year period, with one-third of the shares vesting on each of the first, second and third anniversaries of the Grant Date. The vesting of the stock option will be subject to the employee's continued employment with INOVIO on the applicable vesting dates. This award is subject to the terms and conditions of a stock option agreement under the Inducement Plan.

About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.

Contacts
Media: Jennie Willson, (267) 429-8567, communications@inovio.com
Investors: Peter Vozzo - ICR Healthcare, (443) 213-0505, investor.relations@inovio.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-reports-inducement-grant-under-inducement-plan-302601463.html

SOURCE INOVIO Pharmaceuticals, Inc.

FAQ

What did INOVIO (INO) grant on October 31, 2025?

INOVIO granted a stock option to purchase 3,000 shares with a grant date of October 31, 2025 under its 2022 Inducement Plan.

What is the exercise price of the INO inducement option granted on October 31, 2025?

The exercise price is $2.35, equal to INOVIO's closing common stock price on October 31, 2025.

How does the INOVIO (INO) inducement option vest?

The option vests over three years, with one-third of the shares vesting on each anniversary of the grant date, subject to continued employment.

Under which plan was the INOVIO October 31, 2025 award made?

The award was made under INOVIO's 2022 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Who is eligible for the INOVIO inducement grant announced October 31, 2025?

The announced award was made to a newly hired employee as an inducement grant under the 2022 Inducement Plan.

Are there employment conditions for the INOVIO (INO) option vesting?

Yes, vesting is contingent on the employee's continued employment on each applicable vesting date.